First MRIdian System Installed in Europe at VU University Medical Center of Amsterdam

Patient Treatments with MRI-Guided Radiation Therapy to Begin This Spring

ViewRay, Inc. (OTCQB: VRAY) announced today that the VU University Medical Center (VUmc) in Amsterdam has installed a MRIdian system, the world’s first and only clinical MRI-guided radiation therapy system, marking the first MRIdian installation in Europe. Patient treatments at VUmc will commence this Spring.

“MRI guidance is the next big step in radiotherapy and will, for the first time, enable us to adapt the daily treatment plan and see the tumor and surrounding tissues in real time,” said Ben J. Slotman, M.D., Ph.D., professor and chairman of Radiation Oncology at VUmc.

MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of tumors while radiation is delivered. MRIdian is the only clinically-available system in the world that can provide continuous soft-tissue imaging during radiation treatment. This means that, for the first time, doctors are able to see the tumor they are treating continuously, enabling personalized and adaptive radiation therapy.

VUmc intends to use the machine for patients with tumors in the abdomen and chest such as bladder cancer, prostate cancer, renal cancer, pancreatic cancer, rectal cancer, lung cancer and liver metastases. An area of particular interest to the VUmc team is MRI-guided stereotactic body radiotherapy (SBRT), which is the treatment of cancer using higher doses of radiation in a shorter course of therapy than traditional radiation therapy.

Earlier this year the radiotherapy department of the VUmc organized an international symposium on SBRT where more than 240 participants from 26 different countries gathered to listen to leading experts sharing their experience. A part of the day was dedicated to stereotactic radiotherapy using MRI-guidance, which the center has termed “SMART” for stereotactic MRI-guided and adaptive radiotherapy.

“Our team has now installed MRIdian systems in each of our major markets – North America, Asia-Pacific, and Europe – and we congratulate VUmc on their leadership in being the first in Europe,” said Chris A. Raanes, president and CEO of ViewRay Incorporated. “The radiotherapy department of VUmc is known worldwide for its expertise in high-precision radiotherapy and for being at the forefront of new developments in cancer treatment.”